STOCK TITAN

Bausch Health Companies (BHC) Stock News, Jul-Sep 2021

BHC NYSE

Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.

Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.

Rhea-AI Summary

Bausch Health Companies released its annual Environmental, Social and Governance (ESG) Report on Sept. 29, 2021, emphasizing a commitment to sustainability and stakeholder engagement. The report outlines progress in five key areas: Operate with Integrity, Respect the Environment, Advance Global Health, Improve Communities, and Support Employee Growth. Highlights include enhancing Diversity, Equity & Inclusion initiatives, expanding recycling efforts, and product donations during COVID-19. The full report is available on Bausch Health's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.60%
Tags
none
-
Rhea-AI Summary

Bausch Health announced that new Health Economic Outcomes Research (HEOR) data on RELISTOR will be shared at PAINWeek 2021 in Las Vegas from Sept. 7-11, 2021. The research highlights the use of RELISTOR in treating opioid-induced constipation (OIC) in emergency department patients. Three abstracts will be presented, showcasing broad utilization across care settings. RELISTOR, an opioid antagonist, is indicated for OIC in adults, including those with chronic non-cancer pain and advanced illness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.05%
Tags
none
-
Rhea-AI Summary

Bausch Health Companies (NYSE/TSX: BHC) announced participation in several upcoming investor conferences. Executives, including Sam Eldessouky and Joseph C. Papa, will represent the company at the J.P. Morgan European High Yield & Leveraged Finance Conference on Sept. 9, 2021, and the Deutsche Bank 29th Annual Leveraged Finance Conference on Oct. 4, 2021. The Morgan Stanley Global Healthcare Conference is scheduled for Sept. 13, 2021. Live webcasts will be accessible on the company's Investor Relations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
conferences
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) reported second-quarter 2021 revenues of $2.100 billion, a 26% increase year-over-year. However, the company faced a GAAP net loss of $595 million, worsening from $326 million in Q2 2020. Adjusted EBITDA reached $826 million, up 33%. The company announced plans for an IPO of Solta Medical and appointed Thomas J. Appio as CEO of Bausch Pharma. Guidance for 2021 revenue was revised to $8.40 - $8.60 billion, reflecting divestitures and quality issues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.83%
Tags
-
Rhea-AI Summary

Bausch Health is pursuing an initial public offering (IPO) of its Solta Medical business, aiming to pay down debt and unlock value from this high-growth medical aesthetics segment. Solta, which reported 2020 revenues of $253 million and a 32% CAGR from 2017 to 2020, provides advanced skin rejuvenation technologies. The IPO is anticipated in Q4 2021 or H1 2022, depending on market conditions. Scott A. Hirsch has been appointed CEO of Solta as Bausch Health prepares for this strategic move.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.83%
Tags
-
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced plans to reduce its debt by $350 million through the redemption of senior notes due Sept. 2, 2021. This redemption will utilize cash on hand and funds generated from operations. The company has redeemed a total of $1 billion in debt in 2021, enhancing its financial position. An irrevocable notice of redemption will be issued, with payments processed via the Depository Trust Company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.83%
Tags
none
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) has finalized the sale of its equity interests in Amoun Pharmaceutical Company to Abu Dhabi-based ADQ, yielding approximately $740 million, subject to adjustments. This strategic move is set to allow Bausch Health to reduce its overall debt. CEO Joseph C. Papa emphasized the company's commitment to enhancing shareholder value and preparing for the planned spinoff of Bausch + Lomb. The transaction follows a definitive agreement made earlier in March 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.37%
Tags
none
-
Rhea-AI Summary

Bausch Health Companies (NYSE/TSX: BHC) announced the recipients of its 2021 Aspire Higher scholarship program, awarding scholarships of up to $10,000 to nine students affected by dermatologic conditions. This initiative aims to support these students in achieving their academic goals. Since its inception in 2012, the program has awarded $648,000 in total. The chosen recipients were selected from nearly 150 applications based on their personal essays. The program recognizes a diverse range of educational pursuits across various scholarship categories.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
-
Rhea-AI Summary

Bausch Health Companies Inc. (NYSE/TSX: BHC) announced the winners of its 2021 Salix Gastrointestinal Health Scholars Program, awarding $100,000 in scholarships to ten students with gastrointestinal (GI) diseases. Each recipient will receive $10,000 to support their higher education goals. The competitive selection process considered over 150 applications, highlighting the personal challenges faced by students due to their GI conditions. Salix Pharmaceuticals aims to assist these students in overcoming educational hurdles, reflecting the company’s commitment to improving the lives of those living with GI diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
none
Rhea-AI Summary

Bausch + Lomb, part of Bausch Health Companies (NYSE/TSX: BHC), will present 14 scientific posters on its ophthalmic surgical technologies at the American Society of Cataract and Refractive Surgery annual meeting from July 23-27, 2021, in Las Vegas. These presentations cover key areas such as the clinical performance of IOL platforms and the impact of COVID-19 on surgeries. The event marks a significant return to in-person scientific exchanges, emphasizing the company's commitment to research and improved patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none

FAQ

What is the current stock price of Bausch Health Companies (BHC)?

Bausch Health Companies (BHC) last closed at $8.22.

What is the market cap of Bausch Health Companies (BHC)?

The market cap of Bausch Health Companies (BHC) is approximately $3.1B.